GlobeNewswire by notified

Eimskip: Reduction of share capital

Share

Reference is made to a press release from 9 March 2023 on the results of the Company‘s Annual General Meeting approving to reduce the Company’s share capital by ISK 5,200,000 and the share capital being reduced to 167,850,000 nominal value. The share capital will be reduced by decreasing the Company‘s treasury shares and by a decrease of capital with cash payment to shareholders.

The Register of Enterprises of the Icelandic Revenue and Customs has now approved to grant the Company an exemption from the duty to issue a call to shareholders, cf. Article 53.2 of the Act no. 2/1995 respecting Public Limited Companies.

Reduction of treasury shares

The Company‘s treasury shares will be reduced by ISK 1,700,000 and will post reduction be ISK 1,761,307. The share capital will be reduced from ISK 173,050,000 to ISK 171,350,000 nominal value in relation to this reduction. Prior to this treasury shares amounted to 2.0% of total issued shares but will after the reduction amount to 1.05% of total issued share capital. An application has been sent to Nasdaq and the reduction of Company‘s treasury shares will be executed on Tuesday 25 April 2023. We also refer to a Market Notice that will be issued by Nasdaq Iceland regarding the decrease.

Reduction of capital with cash payment to shareholders

This reduction of capital will amount to ISK 3,500,000 nominal value with cash payment in the amount of ISK 1,925,000,000. The amount will on 26 April 2023 be paid to shareholders proportionally in accordance with their shareholding as registered in the Company‘s share registry at the end of the date of 25 April 2023. The amount of share capital reduction in the excess of nominal value will be recognized as a reduction of share premium or ISK 1,921,500,000

The last business day where the Company‘s shares will be trading with the right to payment regarding the reduction of share capital will be Friday 21 April 2023. The execution of this reduction will be as follows:

  • X-date 24 April 2023
  • Record date 25 April 2023
  • Reduction date 26 April 2023
  • Pay date 26 April 2023
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Oxurion Publishes 2022 Annual Report31.3.2023 20:42:16 CEST | Press release

Regulated Information Leuven, BELGIUM,Boston, MA, US–March 31, 2023– 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2022. The annual report for the year ending December 31, 2022 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeut

Nokia Corporation: Repurchase of own shares on 31.03.202331.3.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 31 March 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 31.03.2023 Espoo, Finland – On 31 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL221,1864.49CEUX21,0654.50AQEU12,3894.49TQEX7,3604.50Total262,0004.49 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 a

Fly Play hf.: Amendments to share option plan31.3.2023 20:00:00 CEST | Press release

Amendments to share option plan As detailed in the Company Description in relation to the listing of shares in Fly Play hf. on Nasdaq First North Iceland, dated June 2021, the Company had, in accordance with the remuneration then in force, implemented a share-based incentive program in the form of option rights whereby the Company granted several members of the management team and other key employees options to purchase shares in the Company as part of their remuneration. Having regard for the purposes of the share-based incentive program referred to above, the Board of Directors has decided to extend the exercise period in relation to share options to purchase a total of 16.666.669 shares in the Company, at a purchase price of ISK 8 per share. For a period of 12 months, these options are therefore exercisable until April 2024, at which point the options expire. The options may be exercised at any time during the exercise period.

SBM Offshore completes US$1.63 billion financing of Almirante Tamandaré31.3.2023 19:25:15 CEST | Press release

March 31, 2023 SBM Offshore is pleased to announce it has signed the project financing of FPSO Almirante Tamandaré for a total of US$1.63 billion. The project financing is provided by a consortium of 13 international banks with insurance cover from 4 international Export Credit Agencies (ECA). The financing is composed of five separate facilities with a ca. 6.3% weighted average cost of debt and a 14-year post-completion maturity for both the ECA covered facilities and the uncovered facility. The FPSO’s design incorporates SBM Offshore’s industry leading Fast4Ward® new build, multi-purpose hull. It will be the largest oil producing unit in Brazil with a processing capacity of 225,000 barrels of oil and 12 million m3 of gas per day. The FPSO will have an estimated greenhouse gas (GHG) emission intensity below 10 kgCO2e/boe1 and will benefit from emission reduction technologies such as the closed flare technology which increases gas utilization, preventing it from being burnt into the at